Table 5 |
||||||||||
|
External validation of immune response prognostic module: distribution of poor and good outcome patients in over-and-underexpressed subgroups |
||||||||||
|
Gene |
UPP |
JRH-2 |
Combined |
|||||||
|
|
||||||||||
|
Poor |
Good |
P |
Poor |
Good |
P |
Poor |
Good |
P |
||
|
|
||||||||||
|
IGLC2 |
High |
0 |
12 |
0.04 |
0 |
7 |
0.09 |
0 |
19 |
0.003 |
|
Low |
6 |
13 |
6 |
11 |
12 |
24 |
||||
|
LY9 |
High |
1 |
16 |
0.05 |
0 |
6 |
0.14 |
1 |
22 |
0.007 |
|
Low |
5 |
9 |
6 |
12 |
11 |
21 |
||||
|
TNFRSF17 |
High |
1 |
16 |
0.05 |
0 |
10 |
0.02 |
1 |
26 |
0.001 |
|
Low |
5 |
9 |
6 |
8 |
11 |
17 |
||||
|
C1QA |
High |
0 |
12 |
0.04 |
0 |
9 |
0.04 |
0 |
21 |
0.001 |
|
Low |
6 |
13 |
6 |
9 |
12 |
22 |
||||
|
|
||||||||||
|
Teschendorff et al. Genome Biology 2007 8:R157 doi:10.1186/gb-2007-8-8-r157 |
||||||||||
